Cargando…

Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway

Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare, neuroendocrine tumors derived from adrenal or extra-adrenal chromaffin cells, respectively. Metastases are discovered in 3-36% of patients at the time of diagnosis. Currently, only suboptimal treatment options exist. Therefore, new therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pang, Ying, Yang, Chunzhang, Schovanek, Jan, Wang, Herui, Bullova, Petra, Caisova, Veronika, Gupta, Garima, Wolf, Katherine I., Semenza, Gregg L., Zhuang, Zhengping, Pacak, Karel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410225/ https://www.ncbi.nlm.nih.gov/pubmed/28423608 http://dx.doi.org/10.18632/oncotarget.16224

Ejemplares similares

Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
por: Bullova, Petra, et al.
Publicado: (2016)

Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha
por: Zhang, Chao, et al.
Publicado: (2017)

Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
por: Liu, Yang, et al.
Publicado: (2020)

A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2(V617F) positive polycythemia vera: a case report
por: Pang, Ying, et al.
Publicado: (2018)

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
por: Pang, Ying, et al.
Publicado: (2019)

Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy
por: Uher, Ondrej, et al.
Publicado: (2021)

High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma
por: Giubellino, Alessio, et al.
Publicado: (2014)

PRDX2 and PRDX4 are negative regulators of hypoxia-inducible factors under conditions of prolonged hypoxia
por: Luo, Weibo, et al.
Publicado: (2016)

Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice
por: Bullova, Petra, et al.
Publicado: (2017)

Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy
por: Uher, Ondrej, et al.
Publicado: (2023)

Hypoxia-inducible factors enhance glutamate signaling in cancer cells
por: Hu, Hongxia, et al.
Publicado: (2014)

A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia
por: Yu, Jiong, et al.
Publicado: (2020)

The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40
por: Caisova, Veronika, et al.
Publicado: (2019)

Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells
por: Zhang, Chuanzhao, et al.
Publicado: (2016)

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy
por: Xu, Hui, et al.
Publicado: (2015)

Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2021)

Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma
por: Giubellino, Alessio, et al.
Publicado: (2013)

SUN-330 Non-Mosaic Somatic HIF2A Mutations Associated with Late-Onset Polycythemia-Paraganglioma Syndrome: Newly Recognized Subclass of Polycythemia-Paraganglioma Syndrome
por: Pang, Ying, et al.
Publicado: (2019)

Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype
por: Xiang, Lisha, et al.
Publicado: (2014)

Hypoxia and glioblastoma therapy
por: Yang, Chunzhang, et al.
Publicado: (2015)

Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia
por: Yang, Chunzhang, et al.
Publicado: (2015)

Systemic Immune Response in Murine Bilateral Pheochromocytoma Model During Immunotherapy Based on a Combination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibodies (MBTA Therapy)
por: Uher, Ondrej, et al.
Publicado: (2021)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

A Transgenic Mouse Model of Pacak–Zhuang Syndrome with An Epas1 Gain-of-Function Mutation
por: Wang, Herui, et al.
Publicado: (2019)

New insights on the pathogenesis of paraganglioma and pheochromocytoma
por: Kantorovich, Vitaly, et al.
Publicado: (2018)

HIF-1α and TAZ serve as reciprocal co-activators in human breast cancer cells
por: Xiang, Lisha, et al.
Publicado: (2015)

Heat acclimation and cross tolerance to hypoxia: Bridging the gap between cellular and systemic responses
por: Ely, Brett R, et al.
Publicado: (2014)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
por: Blanchet, Elise M., et al.
Publicado: (2012)

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
por: Ilanchezhian, Maran, et al.
Publicado: (2020)

Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging
por: Alrezk, Rami, et al.
Publicado: (2018)

Murine Models and Cell Lines for the Investigation of Pheochromocytoma: Applications for Future Therapies?
por: Korpershoek, Esther, et al.
Publicado: (2012)

The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study
por: Schovanek, Jan, et al.
Publicado: (2014)

Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
por: Lookian, Pashayar P., et al.
Publicado: (2021)

Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells
por: Bechmann, Nicole, et al.
Publicado: (2019)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

PSAT089 Lack of Effect of Metformin in Murine Pheochromocytoma Model
por: Ghayee, Hans K, et al.
Publicado: (2022)

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma
por: Mamilla, Divya, et al.
Publicado: (2019)

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
por: Lohse, Ines, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ipigpuk5hvvnluca6rq7ip25cd